Skip to main content
Caplight Logo









LinusBio

LinusBio

Private
New JerseyHealthcare & Life Scienceshttps://www.linusbio.com/

Last Round

VC Round

Jun 16, 2025

Est. Valuation

$170M

Total Funding Raised

$24M

Company Overview

LinusBio is a biotechnology company that provides a precision exposome medicine platform to analyze the molecular impact of environmental exposures on health, with applications in diagnosing and treating complex disorders.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

precision medicineexposome sequencingdiagnostic platformbiomarker discoveryautism spectrum disorderASDclinical diagnosticsmolecular diagnosticsCLIA laboratoryneurodevelopmental disordersAI diagnosticsdigital biomarkersclinical trial supporthealth techbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LinusBio Comparables

Compare LinusBio with similar companies based on industry and business-model similarity.

LinusBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MARAbio
81%
BioROSA Technologies
79%
NeuroQure
78%

LinusBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 16, 2025
VC RoundAug 12, 2024
Series A ExtensionMay 31, 2023
Series AJan 12, 2023

Key People

Founding team and executive leadership

David Bellet

Advisor To Linus Bio CEO

Executive Team

Victoria Polyanskaya

Chief Operating Officer

Executive Team

LinusBio Investors

Notable investors and investment history

LinusBio investors
InvestorRounds
GreatPoint VenturesSeries A
GreatPoint VenturesSeries A
Bow CapitalSeries A Extension, Series A
Divergent InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 5, 2025

    Partnered with Coralis Health to advance autism detection.

  • Jun 16, 2025

    $3M raised in a VC Round.

LinusBio Filings

Explore SEC and related filing metadata, where available.

LinusBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about LinusBio's valuation, stock price, and market status.

Is LinusBio a public or private company?

LinusBio is a private company.

What is the current stock price of LinusBio?

LinusBio is a private company, so its shares have no public market price. Caplight tracks LinusBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is LinusBio worth (valuation)?

LinusBio's valuation is estimated at $170.0M based on funding round data.

Can I buy LinusBio stock?

LinusBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was LinusBio's last funding round?

LinusBio's most recent funding round was VC Round on June 16, 2025.

Who are the main investors in LinusBio?

Key investors in LinusBio include GreatPoint Ventures, GreatPoint Ventures, Bow Capital.

Will LinusBio IPO soon?

No public IPO plans have been announced for LinusBio.

How can I track LinusBio secondary market activity?

Caplight tracks bids, offers, and trades in LinusBio's shares on secondary markets.

Firmographic Details

HeadquartersNew Jersey
Employee Range24
Year Founded2020
Last FundingJun 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?